Navigation Links
FDA Approves Merz Pharmaceuticals' Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Date:8/2/2010

nd previously treated patients and blepharospasm in adults previously treated with Botox® (onabotulinumtoxinA). Please see important safety information below.

More than 84,000 patients have been treated with XEOMIN worldwide since 2005. The U.S. is the 20th country to approve XEOMIN for the treatment of cervical dystonia and blepharospasm.

Important Safety Information About XEOMIN

WARNING: Distant Spread of Toxin Effect

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.  See full prescribing information for complete boxed warning.

WARNINGS AND PRECAUTIONS

  • The potency Units of XEOMIN are not interchangeable with other preparations of botulinum toxin products.  Therefore, units of biological activity of XEOMIN cannot be compared to or converted into units of any other botulinum toxin products.
  • Spread of toxin effects may cause swallowing and breathing difficulties that can lead to death. Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties. Use with caution in patients with compromised respiratory function or dysphagia. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
  • Hypersensitivity reac
    '/>"/>

SOURCE Merz Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 Research and Markets ... the "Latest Regulations on Pharmaceutical International Multi-Center ... offering. This is first time in ... on international multi-center clinical trials of drugs in ... to be implemented on March 1, 2015. The ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x377m/north_american ) has announced the addition of ... by Type (Ankle Replacement, Digit Replacement, Elbow ... - Forecast to 2019" report to ... market for knee replacement was valued at ...
Breaking Medicine Technology:2015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... Group,(Debiopharm), a global biopharmaceutical development specialist that,focuses ... announces,the filing of an application with the ... 6-month formulation of Decapeptyl(R) (triptorelin pamoate 22.5 ... for the treatment of,locally advanced or metastatic, ...
... LOS ANGELES, Sept. 24 International Medical,Corps was ... the Top 25,Members Projects, ,Saving the Lives of ... of 1,190 submissions nominated by American Express card ... by September 29 will vie for $2.5,million in ...
Cached Medicine Technology:Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients 2International Medical Corps Matched with Top 25 American Express Members Project, 'Saving the Lives of Malnourished Children' 2
(Date:5/23/2015)... CA (PRWEB) May 23, 2015 With ... small businesses, are finding it increasingly difficult to provide ... which fail to provide adequate insurance for employees stand ... businesses been such an integral part of a business’s ... affordable healthcare for businesses, Online USA Doctors has created ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at ... the 2015 Congress of Future Medical Leaders in Boston, ... of “America’s highest achieving high school students.” , “I’m ... new goals and learn better study habits,” said Omar. ... which we can ask the surgeons questions.” , The ...
(Date:5/22/2015)... PITTSBURGH, Pa (PRWEB) May 22, 2015 ... Network (AHN) today announced a new partnership to ... program for the region. The initiative includes a new ... BodyStage live demonstration theater, and a new traveling ... in the fall of 2015. , Designed to ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Just 45 minutes more shut-eye a night might make a ... While the connection between a child,s weight and the amount ... new research has found a strong correlation between the two. ... a night had a 23 percent rate of obesity, while ...
... company says drug still has benefits , , MONDAY, Nov. ... Trasylol, a clotting drug using during heart surgery to prevent ... and Drug Administration to remove the drug from the American ... patient population in which the use of Trasylol (aprotinin) outweighs ...
... In a subset of patients suffering heart attack, ... treatment window ends isn,t justified, say researchers from Duke ... last year,s widely reported Occluded Artery Trial (OAT), which ... attacks if it were used more than 3 days ...
... HONG KONG, Nov. 5 Mass Financial Corp. ... a lawsuit in the Supreme Court of,British Columbia, ... for breach of contract and contract interference. In ... Michael Smith, President of MASS said the ...
... - Operating earnings up 9 percent to $490 million, - Diluted earnings ... ... ... Supply Chain ...
... 5 Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today reported ... months ended September 30, 2007, the,Company reported a net loss ... net loss of $8.1 million, or ($0.15) per share, for ... 30, 2007, the Company,reported a net loss of $28.1 million, ...
Cached Medicine News:Health News:Kids Who Skimp on Sleep Tend to Be Fatter 2Health News:Kids Who Skimp on Sleep Tend to Be Fatter 3Health News:Trasylol Pulled From Worldwide Market 2Health News:Trasylol Pulled From Worldwide Market 3Health News:Trasylol Pulled From Worldwide Market 4Health News:Delayed angioplasty -- big bucks, no bang 2Health News:Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages 2Health News:Cardinal Health Reports First Quarter Results 2Health News:Cardinal Health Reports First Quarter Results 3Health News:Cardinal Health Reports First Quarter Results 4Health News:Cardinal Health Reports First Quarter Results 5Health News:Cardinal Health Reports First Quarter Results 6Health News:Cardinal Health Reports First Quarter Results 7Health News:Cardinal Health Reports First Quarter Results 8Health News:Cardinal Health Reports First Quarter Results 9Health News:Cardinal Health Reports First Quarter Results 10Health News:Cardinal Health Reports First Quarter Results 11Health News:Cardinal Health Reports First Quarter Results 12Health News:Cardinal Health Reports First Quarter Results 13Health News:Cardinal Health Reports First Quarter Results 14Health News:Cardinal Health Reports First Quarter Results 15Health News:Cardinal Health Reports First Quarter Results 16Health News:Cardinal Health Reports First Quarter Results 17Health News:Cardinal Health Reports First Quarter Results 18Health News:Cardinal Health Reports First Quarter Results 19Health News:Cardinal Health Reports First Quarter Results 20Health News:Cardinal Health Reports First Quarter Results 21Health News:Cardinal Health Reports First Quarter Results 22Health News:Cardinal Health Reports First Quarter Results 23Health News:Cardinal Health Reports First Quarter Results 24Health News:Cardinal Health Reports First Quarter Results 25Health News:Cardinal Health Reports First Quarter Results 26Health News:Cardinal Health Reports First Quarter Results 27Health News:Cardinal Health Reports First Quarter Results 28Health News:Cardinal Health Reports First Quarter Results 29
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: